Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo shows promise for Hard-to-Treat cancers

NCT ID NCT04123366

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had already tried standard treatments without success. The results could help identify which patients might benefit from this approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
olaparib (a PARP inhibitor) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have specific DNA repair defects.
What could go wrong
This is a phase 2 trial, so results are still early. The combination may not work for all tumor types and could cause side effects like fatigue, nausea, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

333 people

The number who actually took part.

Started

Nov 2019

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor (except breast or ovarian cancers whose tumor has a germline or somatic BRCA mutation) that is not eligible for curative treatment and for which standard of care therapy has failed. Participants must have progressed on or be intolerant to standard of care therapies that are known to provide clinical benefit. There is no limit on the number of prior treatment regimens. * Has either centrally-confirmed known or suspected deleterious mutations in ≥1 of the specified 15 genes involved in HRR or centrally-confirmed HRD based on the Lynparza HRR-HRD assay. * Has measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology and confirmed in real time by blinded independent central review (BICR). BICR must confirm the presence of radiologically measurable disease per RECIST 1.1 for the participant to be eligible for the study. * Has a life expectancy of ≥3 months. * Must have had CR or PR while on the last treatment with prior cisplatin or carboplatin, or if received only oxaliplatin had CR, PR, or stable disease (SD) while on the last treatment with prior oxaliplatin (either as monotherapy or in combination) for advanced (metastatic and/or unresectable) solid tumor. Participant must also not have been refractory to prior platinum-containing therapy. * Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1, as assessed within 3 days of study treatment initiation. * Male participants must agree to use contraception during the treatment period and for ≥90 days (3 months) after the last dose of olaparib and refrain from donating sperm during this period. * Female participants must not be pregnant or breastfeeding, and ≥1 of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP who agrees to use contraception during the treatment period and for ≥120 days (3 months) after the last dose of pembrolizumab and 180 days (6 months) after the last dose of olaparib, has a highly sensitive pregnancy test within 24 hours for urine or within 72 hours for serum before the first dose of study intervention, and abstains from breastfeeding during the study intervention period and for at least 120 days after the last dose of the study intervention. * Has adequate organ function Exclusion Criteria: * Has a known additional malignancy that is progressing or has required active treatment in the last 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal carcinoma in situ, or cervical carcinoma in situ that has undergone potentially curative therapy are not excluded. * Has a history of non-infectious pneumonitis/interstitial lung disease that required treatment with steroids or currently has pneumonitis/interstitial lung disease. * Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML. * Has known central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has an active infection requiring systemic therapy. * Has active tuberculosis (Bacillus tuberculosis \[TB\]). * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing \>10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Has an active autoimmune disease that has required systemic treatment in the past 2 years. * Has received colony-stimulating factors (e.g. granulocyte colony-stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor \[GM-CSF\] or recombinant erythropoietin) within 28 days prior to the first dose of study treatment. * Has a known history of human immunodeficiency virus (HIV) infection. * Has known active hepatitis B or hepatitis C. * Is unable to swallow orally administered medication or has a gastrointestinal (GI) disorder affecting absorption (e.g. gastrectomy, partial bowel obstruction, malabsorption). * Has received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-programmed death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], OX 40 \[Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4)\], CD137 \[tumor necrosis factor receptor superfamily member 9 (TNFRSF9)\]). * Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (poly\[ADP ribose\]) polymerization (PARP) inhibitor. * Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to administration of study treatment. * Must have recovered from all adverse events (AEs) due to previous therapies, excluding alopecia, to ≤Grade 1 or Baseline. * Has a known hypersensitivity to the study treatments and/or any of their excipients. * Is currently receiving either strong inhibitors of cytochrome P450 (CYP)3A4 (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate inhibitors of CYP3A4 (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 2 weeks. * Is currently receiving either strong inducers of CYP3A4 (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate inducers of CYP3A4 (e.g. bosentan, efavirenz, modafinil) that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents. * Has received previous allogenic bone-marrow transplant or double umbilical cord transplantation (dUCBT). * Has received a whole blood transfusion in the last 120 days prior to entry to the study. * Has received prior radiotherapy within 2 weeks of start of study treatment. * Is currently enrolled in and receiving study therapy, was enrolled in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks (28 days) of the first dose of study treatment. * The presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT interval by Fredericia \[QTcF\] prolongation \>500 msec, electrolyte disturbances), or participant has congenital long QT syndrome. * Has either had major surgery within 2 weeks of starting study treatment or has not recovered from any effects of any major surgery. * Has received a live vaccine within 30 days prior to the first dose of study treatment. * Has had an allogenic tissue/solid tumor organ transplant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumors

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda ( Site 0700)

    Milan, 20162, Italy

  • Ad-Vance Medical Research LLC ( Site 0505)

    Ponce, 00717, Puerto Rico

  • Aichi Cancer Center Hospital ( Site 2504)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Akademiska Sjukhuset ( Site 2002)

    Uppsala, Uppsala County, 751 85, Sweden

  • Akdeniz Universitesi Tıp Fakultesi ( Site 1503)

    Antalya, 07070, Turkey (Türkiye)

  • Ankara Sehir Hastanesi ( Site 1508)

    Ankara, 06800, Turkey (Türkiye)

  • Atlantic Health System ( Site 0046)

    Summit, New Jersey, 07901, United States

  • Azienda Ospedaliera Universitaria Senese ( Site 0704)

    Siena, 53100, Italy

  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0703)

    Modena, Emilia-Romagna, 41124, Italy

  • BC Cancer-Vancouver Center ( Site 0203)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Banner MD Anderson Cancer Center ( Site 0049)

    Gilbert, Arizona, 85234, United States

  • Banner MD Anderson Cancer Center ( Site 0092)

    Greeley, Colorado, 80631, United States

  • Baskent University Adana Training Hospital ( Site 1509)

    Adana, 01250, Turkey (Türkiye)

  • Blacktown Hospital ( Site 2202)

    Blacktown, New South Wales, 2148, Australia

  • CEMIC ( Site 2701)

    Buenos Aires, C1431FWO, Argentina

  • CHD Vendee ( Site 0604)

    La Roche-sur-Yon, Vendee, 85925, France

  • CHU Jean Minjoz ( Site 0606)

    Besançon, Doubs, 25030, France

  • CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 3103)

    Mexico City, 06100, Mexico

  • Cancercare Rondebosch Oncology ( Site 1901)

    Rondebosch, Western Cape, 7700, South Africa

  • Centre Henri Becquerel ( Site 0607)

    Rouen, Seine-Maritime, 76038, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0201)

    Montreal, Quebec, H2X 1R9, Canada

  • Centro Medico Dra De Salvo ( Site 2702)

    Buenos Aires, C1426ABP, Argentina

  • Centro Medico Integral De Cancerología (CEMIC) ( Site 3002)

    Quetzaltenango, 09002, Guatemala

  • Centro Medico Zambrano Hellion ( Site 3105)

    San Pedro Garza García, Nuevo León, 66278, Mexico

  • Centro Oncologico Riojano Integral ( Site 2703)

    La Rioja, F5300COE, Argentina

  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 3101)

    Madero, Tamaulipas, 89440, Mexico

  • Chaim Sheba Medical Center ( Site 0800)

    Ramat Gan, 5262000, Israel

  • Charite-Universitaetsmedizin Berlin-Campus Benjamin Franklin ( Site 0902)

    Berlin, 12203, Germany

  • Cherkasy Regional Oncology Dispensary ( Site 1702)

    Cherkasy, Cherkasy Oblast, 18009, Ukraine

  • Clinica Integral Internacional de Oncologia S. de R.L. de C.V. ( Site 3107)

    Puebla City, 72530, Mexico

  • Clinica San Gabriel ( Site 3202)

    Lima, 15088, Peru

  • Clinica de la Costa S.A.S. ( Site 2900)

    Barranquilla, Atlántico, 080020, Colombia

  • Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Communal non profit enterprise Regional Clinical Oncology Center ( Site 1704)

    Kharkiv, Kharkiv Oblast, 61070, Ukraine

  • Daugavpils Regional Hospital ( Site 2104)

    Daugavpils, 5417, Latvia

  • Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi ( Site 1501)

    Izmir, 35040, Turkey (Türkiye)

  • FDI Clinical Research ( Site 0500)

    San Juan, 00927, Puerto Rico

  • Fundacion CIDEA ( Site 2704)

    Ciudad de Buenos Aires, Buenos Aires F.D., C1121ABE, Argentina

  • Fundacion Cardiovascular de Colombia ( Site 2907)

    Piedecuesta, Santander Department, 68017, Colombia

  • Fundacion Valle del Lili ( Site 2909)

    Cali, Valle del Cauca Department, 760032, Colombia

  • Fundación Colombiana de Cancerología Clínica Vida ( Site 2902)

    Medellín, Antioquia, 050030, Colombia

  • Gazi Universitesi Tip Fakultesi ( Site 1507)

    Ankara, 06500, Turkey (Türkiye)

  • Grupo Angeles SA ( Site 3004)

    Guatemala City, 01015, Guatemala

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 1505)

    Istanbul, 34722, Turkey (Türkiye)

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1502)

    Ankara, 06100, Turkey (Türkiye)

  • Hadassah Ein Kerem Medical Center ( Site 0802)

    Jerusalem, 9112001, Israel

  • Hemato Oncologos S.A. ( Site 2910)

    Cali, Valle del Cauca Department, 76001, Colombia

  • Hematology and Oncology Institute ( Site 0504)

    Manati, 00674, Puerto Rico

  • Hokkaido University Hospital ( Site 2502)

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospital Britanico de Buenos Aires ( Site 2705)

    Ciudad de Buenos Aires, Buenos Aires F.D., C1280AEB, Argentina

  • Hospital Clinic i Provincial ( Site 1302)

    Barcelona, 08036, Spain

  • Hospital General Universitario Gregorio Maranon ( Site 1300)

    Madrid, 28007, Spain

  • Hospital H+ Queretaro ( Site 3104)

    Querétaro City, Querétaro, 76000, Mexico

  • Hospital Nacional Adolfo Guevara Velasco ( Site 3205)

    Cuzco, Qusqu, 08003, Peru

  • Hospital Nacional Arzobispo Loayza ( Site 3208)

    Lima, 15082, Peru

  • Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)

    Arequipa, Ariqipa, 04001, Peru

  • Hospital Nacional Cayetano Heredia ( Site 3203)

    Lima, 15102, Peru

  • Hospital Nacional Daniel Alcides Carrion ( Site 3207)

    Bellavista, Qallaw, 07021, Peru

  • Hospital Quiron de Madrid ( Site 1301)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Inonu Universitesi Medical Fakultesi ( Site 1506)

    Malatya, 44280, Turkey (Türkiye)

  • Inova Schar Cancer Institute ( Site 0008)

    Fairfax, Virginia, 22031, United States

  • Institut Gustave Roussy ( Site 0602)

    Villejuif, Val-de-Marne, 94800, France

  • Institut du Cancer de Montpellier ( Site 0610)

    Montpellier, Herault, 34298, France

  • Instituto Nacional de Enfermedades Neoplasicas ( Site 3201)

    Lima, 15038, Peru

  • Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1101)

    Cluj-Napoca, Cluj, 400015, Romania

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1504)

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Nazionale Tumori Fondazione Pascale ( Site 0705)

    Naples, 80131, Italy

  • Japanese Foundation for Cancer Research ( Site 2503)

    Tokyo, 135-8550, Japan

  • Karolinska Universitetssjukhuset Solna ( Site 2000)

    Solna, Stockholm County, 171 76, Sweden

  • Khmelnitskiy Regional Onkology Dispensary ( Site 1705)

    Khmelnitskiy, Khmelnytskyi Oblast, 29009, Ukraine

  • Kirovograd Regional oncology Dispensary ( Site 1716)

    Kropyvnytsky, Kirovohrad Oblast, 25011, Ukraine

  • Kyushu University Hospital ( Site 2506)

    Fukuoka, 812-8582, Japan

  • Liepaja Regional Hospital ( Site 2101)

    Liepāja, 3414, Latvia

  • Linear Clinical Research Ltd ( Site 2206)

    Nedlands, Western Australia, 6009, Australia

  • Mary Potter Oncology Centre, Little Company of Mary Hospital ( Site 1900)

    Pretoria, Gauteng, 0181, South Africa

  • Medi-K Cayala ( Site 3005)

    Guatemala City, 01016, Guatemala

  • Medical Centre Consilium Medical ( Site 1712)

    Kyiv, Kyivska Oblast, 04050, Ukraine

  • Medical center of the Limited Liability Company Yulis ( Site 1714)

    Zaporizhzhia, Zaporizhzhia Oblast, 69035, Ukraine

  • Medisprof ( Site 1102)

    Cluj-Napoca, Cluj, 400641, Romania

  • Meir Medical Center ( Site 0804)

    Kfar Saba, 4428164, Israel

  • Monash Medical Centre ( Site 2205)

    Clayton, Victoria, 3168, Australia

  • Moncton Hospital - Horizon Health Network ( Site 0206)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1700)

    Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital ( Site 2501)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 2500)

    Kashiwa, Chiba, 277-8577, Japan

  • Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1510)

    Konya, 42080, Turkey (Türkiye)

  • New York Cancer and Blood Specialists-Research Department ( Site 0080)

    Port Jefferson Station, New York, 11776, United States

  • Northeast Georgia Medical Center ( Site 0026)

    Gainesville, Georgia, 30501, United States

  • Northwest Georgia Oncology Centers PC ( Site 0047)

    Marietta, Georgia, 30060, United States

  • Northwest Medical Specialties, PLLC ( Site 0007)

    Tacoma, Washington, 98405, United States

  • Norton Cancer Institute - St. Matthews ( Site 0024)

    Louisville, Kentucky, 40207, United States

  • Okayama University Hospital ( Site 2505)

    Okayama, 700-8558, Japan

  • Oncologika S.A. ( Site 3003)

    Guatemala City, 01010, Guatemala

  • Oncosalud ( Site 3200)

    Lima, 15036, Peru

  • P. Stradina Clinical University Hospital ( Site 2102)

    Riga, LV-1002, Latvia

  • Pan American Center for Oncology Trials LLC ( Site 0501)

    Rio Piedras, 00935, Puerto Rico

  • Parkland Health & Hospital System ( Site 0091)

    Dallas, Texas, 75235, United States

  • Podillya Regional Center of Oncology ( Site 1708)

    Vinnytsia, Vinnytsia Oblast, 21029, Ukraine

  • Policlinica Oncomed SRL ( Site 1104)

    Timișoara, Timiș County, 300239, Romania

  • Preparaciones Oncologicas ( Site 3102)

    León, Guanajuato, 37178, Mexico

  • Rabin Medical Center ( Site 0806)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology Division ( Site 0801)

    Haifa, 3109601, Israel

  • Riga East Clinical University Hospital ( Site 2103)

    Riga, 1079, Latvia

  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)

    Craiova, Dolj, 200542, Romania

  • Samsung Medical Center ( Site 2401)

    Seoul, 06351, South Korea

  • San Francisco Oncology Associates ( Site 0085)

    San Francisco, California, 94115, United States

  • Sanatorio Nuestra Senora del Pilar ( Site 3006)

    Guatemala City, 01015, Guatemala

  • Seoul National University Bundang Hospital ( Site 2403)

    Seongnam-si, Kyonggi-do, 13605, South Korea

  • Seoul National University Hospital ( Site 2402)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2400)

    Seoul, 03722, South Korea

  • Skanes Universitetssjukhus Lund. ( Site 2001)

    Lund, Skåne County, 221 85, Sweden

  • Sourasky Medical Center ( Site 0805)

    Tel Aviv, 6423906, Israel

  • Spitalul Judetean de Urgenta Alba Iulia ( Site 1107)

    Alba Iulia, Alba, 510007, Romania

  • Tasman Oncology Research Pty Ltd ( Site 2203)

    Southport, Queensland, 4215, Australia

  • The Kirklin Clinic ( Site 0086)

    Birmingham, Alabama, 35233, United States

  • The Oncology Centre ( Site 1904)

    Durban, KwaZulu-Natal, 4091, South Africa

  • The University of Oklahoma Health Sciences Center ( Site 0050)

    Oklahoma City, Oklahoma, 73104, United States

  • Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1500)

    Edirne, 22030, Turkey (Türkiye)

  • UC Davis Comprehensive Cancer Center ( Site 0039)

    Sacramento, California, 95817, United States

  • Unidad Biomedica Avanzada Monterrey S. A. ( Site 3108)

    Monterrey, Nuevo León, 64460, Mexico

  • Universitaetsklinik Koeln ( Site 0903)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinik der Ludwig-Maximilians-Universitaet Muenchen ( Site 0906)

    Munich, Bavaria, 81377, Germany

  • Universitas Annex National Hospital ( Site 1902)

    Bloemfontein, Free State, 9301, South Africa

  • University Hospitals Cleveland Medical Center ( Site 0016)

    Cleveland, Ohio, 44106, United States

  • University of California San Francisco ( Site 0015)

    San Francisco, California, 94158, United States

  • University of Florida ( Site 0078)

    Gainesville, Florida, 32608, United States

  • University of Texas, Southwestern Medical Center ( Site 0004)

    Dallas, Texas, 75390, United States

  • University of Texas-MD Anderson Cancer Center ( Site 0087)

    Houston, Texas, 77030, United States

  • Uniwersyteckie Centrum Kliniczne ( Site 1809)

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Utah Cancer Specialists ( Site 0038)

    West Valley City, Utah, 84119, United States

  • Vaal Triangle Oncology Centre ( Site 1905)

    Vereeniging, Gauteng, 1930, South Africa

  • Winship Cancer Institute of Emory University ( Site 0057)

    Atlanta, Georgia, 30322, United States

  • Wits Clinical Research ( Site 1906)

    Parktown-Johannesburg, Gauteng, 2193, South Africa

  • Zhytomyr Regional Oncology Center ( Site 1710)

    Zhytomyr, Zhytomyr Oblast, 10002, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.